Aveanna Healthcare Holdings Inc (AVAH)vsAstraZeneca PLC (AZN)
AVAH
Aveanna Healthcare Holdings Inc
$8.48
+0.75%
HEALTHCARE · Cap: $1.84B
AZN
AstraZeneca PLC
$188.41
+1.47%
HEALTHCARE · Cap: $284.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 2297% more annual revenue ($60.44B vs $2.52B). AZN leads profitability with a 17.2% profit margin vs 10.4%. AVAH trades at a lower P/E of 7.0x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AVAH
Buy62
out of 100
Grade: C+
AZN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-84.3%
Fair Value
$4.33
Current Price
$8.48
$4.15 premium
Margin of Safety
+5.9%
Fair Value
$194.57
Current Price
$188.41
$6.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 37 in profit
Earnings expanding 612.0% YoY
15.9% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Distress zone — elevated risk
Elevated debt levels
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AVAH
The strongest argument for AVAH centers on P/E Ratio, Return on Equity, EPS Growth. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AVAH
The primary concerns for AVAH are Market Cap, Free Cash Flow, Altman Z-Score. Debt-to-equity of 6.26 is elevated, increasing financial risk.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AVAH profiles as a growth stock while AZN is a mature play — different risk/reward profiles.
AVAH carries more volatility with a beta of 1.93 — expect wider price swings.
AVAH is growing revenue faster at 15.9% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 62/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Aveanna Healthcare Holdings Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Aveanna Healthcare Holdings Inc., a diversified home care platform company, offers private duty nursing (PDN) services, adult home health and palliative care, pediatric home therapy, and enteral nutrition services in the United States. The company is headquartered in Atlanta, Georgia.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?